Page last updated: 2024-10-29

isradipine and Cardiometabolic Syndrome

isradipine has been researched along with Cardiometabolic Syndrome in 1 studies

Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.

Research Excerpts

ExcerptRelevanceReference
"5-5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome."7.73Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. ( Sirotiaková, J; Widimský, J, 2006)
"5-5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome."3.73Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. ( Sirotiaková, J; Widimský, J, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Widimský, J1
Sirotiaková, J1

Other Studies

1 other study available for isradipine and Cardiometabolic Syndrome

ArticleYear
Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
    Current medical research and opinion, 2006, Volume: 22, Issue:7

    Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Double-Blind Method; Drug Toler

2006